A Study of Experimental FT-2102 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome (types of blood system cancer)
This study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent or in combination with azacitidine or cytarabine.
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, AML, MDS, IDH1, IDH, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Cytarabine, Azacitidine, FT-2102 (olutasidenib), PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine, PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine